A	a	O	O	O	O
selective	selective	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
D4	d4	O	O	O	O
receptor	receptor	O	O	O	O
antagonist	antagonist	O	O	O	O
,	,	O	O	O	O
NRA0160	nra0160	CHEMICALS	O	OTHERS	I
:	:	O	O	O	O
a	a	O	O	O	O
preclinical	preclinical	O	O	O	O
neuropharmacological	neuropharmacological	O	O	O	O
profile	profile	O	O	O	O
.	.	O	O	O	O

NRA0160	nra0160	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
5	5	CHEMICALS	O	OTHERS	I
-	-	CHEMICALS	O	OTHERS	I
[	[	CHEMICALS	O	OTHERS	I
2-	2-	CHEMICALS	O	OTHERS	I
(	(	CHEMICALS	O	OTHERS	I
4-	4-	CHEMICALS	O	OTHERS	I
(	(	CHEMICALS	O	OTHERS	I
3	3	CHEMICALS	O	OTHERS	I
-	-	CHEMICALS	O	OTHERS	I
fluorobenzylidene	fluorobenzylidene	CHEMICALS	O	OTHERS	I
)	)	CHEMICALS	O	OTHERS	I
piperidin-1-yl	piperidin-1-yl	CHEMICALS	O	OTHERS	I
)	)	CHEMICALS	O	OTHERS	I
ethyl	ethyl	CHEMICALS	O	OTHERS	I
]	]	CHEMICALS	O	OTHERS	I
-	-	CHEMICALS	O	OTHERS	I
4	4	CHEMICALS	O	OTHERS	I
-(4-fluorophenyl	-(4-fluorophenyl	CHEMICALS	O	OTHERS	I
)	)	CHEMICALS	O	OTHERS	I
thiazole-2-carboxamide	thiazole-2-carboxamide	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
has	has	O	O	O	O
a	a	O	O	O	O
high	high	O	O	O	O
affinity	affinity	O	O	O	O
for	for	O	O	O	O
human	human	O	O	O	O
cloned	cloned	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
D4.2	d4.2	O	O	O	O
,	,	O	O	O	O
D4.4	d4.4	O	O	O	O
and	and	O	O	O	O
D4.7	d4.7	O	O	O	O
receptors	receptors	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
Ki	ki	O	O	O	O
values	values	O	O	O	O
of	of	O	O	O	O
0.5	0.5	O	O	O	O
,	,	O	O	O	O
0.9	0.9	O	O	O	O
and	and	O	O	O	O
2.7	2.7	O	O	O	O
nM	nm	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
.	.	O	O	O	O

NRA0160	nra0160	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
over	over	O	O	O	O
20,000fold	20,000fold	O	O	O	O
more	more	O	O	O	O
potent	potent	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
D4.2	d4.2	O	O	O	O
receptor	receptor	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
human	human	O	O	O	O
cloned	cloned	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
D2L	d2l	O	O	O	O
receptor	receptor	O	O	O	O
.	.	O	O	O	O

NRA0160	nra0160	CHEMICALS	O	OTHERS	I
has	has	O	O	O	O
negligible	negligible	O	O	O	O
affinity	affinity	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
human	human	O	O	O	O
cloned	cloned	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
D3	d3	O	O	O	O
receptor	receptor	O	O	O	O
(	(	O	O	O	O
Ki=39	ki=39	O	O	O	O
nM	nm	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
rat	rat	O	O	O	O
serotonin	serotonin	CHEMICALS	O	OTHERS	I
(5-HT)2A	(5-ht)2a	O	O	O	O
receptors	receptors	O	O	O	O
(	(	O	O	O	O
Ki=180	ki=180	O	O	O	O
nM	nm	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
rat	rat	O	O	O	O
alpha1	alpha1	O	O	O	O
adrenoceptor	adrenoceptor	O	O	O	O
(	(	O	O	O	O
Ki=237	ki=237	O	O	O	O
nM	nm	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

NRA0160	nra0160	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
clozapine	clozapine	CHEMICALS	O	OTHERS	I
antagonized	antagonized	O	O	O	O
locomotor	locomotor	O	DISEASE	OTHERS	I
hyperactivity	hyperactivity	O	DISEASE	OTHERS	I
induced	induced	O	O	O	O
by	by	O	O	O	O
methamphetamine	methamphetamine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
MAP	map	O	O	OTHERS	I
)	)	O	O	O	O
in	in	O	O	O	O
mice	mice	O	O	O	O
.	.	O	O	O	O

NRA0160	nra0160	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
clozapine	clozapine	CHEMICALS	O	OTHERS	I
antagonized	antagonized	O	O	O	O
MAP-induced	map-induced	O	O	O	O
stereotyped	stereotyped	O	O	O	O
behavior	behavior	O	O	O	O
in	in	O	O	O	O
mice	mice	O	O	O	O
,	,	O	O	O	O
although	although	O	O	O	O
their	their	O	O	O	O
effects	effects	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
exceed	exceed	O	O	O	O
50	50	O	O	O	O
%	%	O	O	O	O
inhibition	inhibition	O	O	O	O
,	,	O	O	O	O
even	even	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
highest	highest	O	O	O	O
dose	dose	O	O	O	O
given	given	O	O	O	O
.	.	O	O	O	O

NRA0160	nra0160	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
clozapine	clozapine	CHEMICALS	O	OTHERS	I
significantly	significantly	O	O	O	O
induced	induced	O	O	O	O
catalepsy	catalepsy	O	DISEASE	OTHERS	I
in	in	O	O	O	O
rats	rats	O	O	O	O
,	,	O	O	O	O
although	although	O	O	O	O
their	their	O	O	O	O
effects	effects	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
exceed	exceed	O	O	O	O
50	50	O	O	O	O
%	%	O	O	O	O
induction	induction	O	O	O	O
even	even	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
highest	highest	O	O	O	O
dose	dose	O	O	O	O
given	given	O	O	O	O
.	.	O	O	O	O

NRA0160	nra0160	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
clozapine	clozapine	CHEMICALS	O	OTHERS	I
significantly	significantly	O	O	O	O
reversed	reversed	O	O	O	O
the	the	O	O	O	O
disruption	disruption	O	O	O	O
of	of	O	O	O	O
prepulse	prepulse	O	O	O	O
inhibition	inhibition	O	O	O	O
(	(	O	O	O	O
PPI	ppi	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
rats	rats	O	O	O	O
produced	produced	O	O	O	O
by	by	O	O	O	O
apomorphine	apomorphine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

NRA0160	nra0160	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
clozapine	clozapine	CHEMICALS	O	OTHERS	I
significantly	significantly	O	O	O	O
shortened	shortened	O	O	O	O
the	the	O	O	O	O
phencyclidine	phencyclidine	O	O	OTHERS	I
(PCP)-induced	(pcp)-induced	O	O	O	O
prolonged	prolonged	O	O	O	O
swimming	swimming	O	O	O	O
latency	latency	O	O	O	O
in	in	O	O	O	O
rats	rats	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
water	water	O	O	O	O
maze	maze	O	O	O	O
task	task	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
findings	findings	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
NRA0160	nra0160	CHEMICALS	O	OTHERS	I
may	may	O	O	O	O
have	have	O	O	O	O
unique	unique	O	O	O	O
antipsychotic	antipsychotic	O	O	O	O
activities	activities	O	O	O	O
without	without	O	O	O	O
the	the	O	O	O	O
liability	liability	O	O	O	O
of	of	O	O	O	O
motor	motor	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
typical	typical	O	O	O	O
of	of	O	O	O	O
classical	classical	O	O	O	O
antipsychotics	antipsychotics	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

